MA53069A1 - Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer - Google Patents

Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Info

Publication number
MA53069A1
MA53069A1 MA53069A MA53069A MA53069A1 MA 53069 A1 MA53069 A1 MA 53069A1 MA 53069 A MA53069 A MA 53069A MA 53069 A MA53069 A MA 53069A MA 53069 A1 MA53069 A1 MA 53069A1
Authority
MA
Morocco
Prior art keywords
antibody
igf
treatment
relates
cancer
Prior art date
Application number
MA53069A
Other languages
English (en)
Other versions
MA53069B1 (fr
Inventor
Charlotte Beau-Larvor
Liliane Goetsch
Matthieu Broussas
Thierry Champion
Alain Robert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA53069A1 publication Critical patent/MA53069A1/fr
Publication of MA53069B1 publication Critical patent/MA53069B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La présente invention concerne un anticorps, en particulier un anticorps monoclonal, pouvant se lier spécifiquement à igf-1r, ainsi que des séquences d'acides aminés et d'acides nucléiques codant pour cet anticorps. Dans un aspect, l'invention concerne un anticorps, ou un fragment de liaison d'antigène de celui-ci, pouvant se lier à l'igf-1r et, par l'induction d'une internalisation d'igf-1r, étant internalisé dans la cellule. L'invention concerne également l'utilisation de cet anticorps en tant que véhicule d'adressage conjugué à d'autres composés anticancéreux, tels que des toxines, des radioéléments ou des médicaments, et l'utilisation de ceux-ci pour le traitement de certains cancers.
MA53069A 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer MA53069B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984160P 2014-04-25 2014-04-25
PCT/EP2015/059050 WO2015162292A1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA53069A1 true MA53069A1 (fr) 2021-10-29
MA53069B1 MA53069B1 (fr) 2022-04-29

Family

ID=53373391

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39378A MA39378B2 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA53069A MA53069B1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA39378A MA39378B2 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Country Status (29)

Country Link
US (2) US10202458B2 (fr)
EP (2) EP3783033A1 (fr)
JP (2) JP6835591B2 (fr)
KR (3) KR102357032B1 (fr)
CN (2) CN112851808A (fr)
AU (1) AU2015250760C1 (fr)
BR (1) BR112016024575B1 (fr)
CA (1) CA2946795C (fr)
CY (1) CY1123743T1 (fr)
DK (1) DK3134438T3 (fr)
ES (1) ES2841249T3 (fr)
HR (1) HRP20202047T1 (fr)
HU (1) HUE052223T2 (fr)
IL (2) IL248357B (fr)
LT (1) LT3134438T (fr)
MA (2) MA39378B2 (fr)
MX (2) MX2016014000A (fr)
MY (1) MY182444A (fr)
NZ (1) NZ725423A (fr)
PL (1) PL3134438T3 (fr)
PT (1) PT3134438T (fr)
RS (1) RS61379B1 (fr)
RU (1) RU2698977C2 (fr)
SA (1) SA516380131B1 (fr)
SI (1) SI3134438T1 (fr)
TN (1) TN2016000445A1 (fr)
UA (1) UA122390C2 (fr)
WO (1) WO2015162292A1 (fr)
ZA (1) ZA201607095B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3134124T1 (sl) * 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
JP6968790B2 (ja) 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ発現癌の処置のための組成物
CN110167966A (zh) 2017-01-06 2019-08-23 克雷森多生物制剂有限公司 程序性细胞死亡(pd-1)的单结构域抗体
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
US20230243836A1 (en) 2018-07-20 2023-08-03 Pierre Fabre Medicament Receptor for vista
JP2022502431A (ja) 2018-09-27 2022-01-11 ピエール、ファーブル、メディカマン スルホマレイミドに基づくリンカーおよび対応する複合体
US20210380605A1 (en) * 2018-10-19 2021-12-09 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20220088847A (ko) 2019-09-04 2022-06-28 주식회사 와이바이오로직스 항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
EP4353220A1 (fr) 2022-10-12 2024-04-17 Pierre Fabre Medicament Utilisation d'une composition aqueuse liquide pour la solubilisation et la stabilisation d'un conjugué anticorps-médicament

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2661000B1 (fr) 1990-04-12 1992-08-07 Aerospatiale Machine d'essais d'eprouvettes en cisaillement.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561427A (en) 1994-12-30 1996-10-01 Psc Inc. Analog to digital converter with continuous conversion cycles and large input signal range
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7612178B2 (en) * 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
WO2008079849A2 (fr) 2006-12-22 2008-07-03 Genentech, Inc. Anticorps liés au récepteur du facteur de croissance semblable à l'insuline
CA2683568A1 (fr) 2007-05-08 2008-11-20 Genentech, Inc. Anticorps anti-muc16 produits avec de la cysteine et conjugues anticorps-medicament
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
ES2430567T3 (es) 2010-04-15 2013-11-21 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados de las mismas
JP5588086B2 (ja) * 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体

Also Published As

Publication number Publication date
JP2017513898A (ja) 2017-06-01
RU2016145277A3 (fr) 2018-12-13
KR102357032B1 (ko) 2022-02-08
TN2016000445A1 (en) 2018-04-04
EP3134438B1 (fr) 2020-09-30
IL274226A (en) 2020-06-30
MA53069B1 (fr) 2022-04-29
CY1123743T1 (el) 2022-03-24
JP2021073279A (ja) 2021-05-13
CN106459204A (zh) 2017-02-22
HRP20202047T1 (hr) 2021-02-19
AU2015250760A1 (en) 2016-11-03
US20170267766A1 (en) 2017-09-21
MX2016014000A (es) 2017-05-30
EP3134438A1 (fr) 2017-03-01
HUE052223T2 (hu) 2021-04-28
AU2015250760B2 (en) 2020-10-22
US11365259B2 (en) 2022-06-21
CA2946795A1 (fr) 2015-10-29
KR20160145110A (ko) 2016-12-19
RU2698977C2 (ru) 2019-09-02
PT3134438T (pt) 2020-12-31
KR20200128210A (ko) 2020-11-11
KR102177436B1 (ko) 2020-11-12
PL3134438T3 (pl) 2021-04-06
BR112016024575B1 (pt) 2024-02-27
CA2946795C (fr) 2021-03-30
JP6835591B2 (ja) 2021-02-24
MY182444A (en) 2021-01-25
LT3134438T (lt) 2021-01-11
MX2021002144A (es) 2021-03-09
US10202458B2 (en) 2019-02-12
WO2015162292A1 (fr) 2015-10-29
SI3134438T1 (sl) 2021-04-30
SA516380131B1 (ar) 2019-12-04
KR20220018620A (ko) 2022-02-15
ZA201607095B (en) 2020-07-29
MA39378B2 (fr) 2021-02-26
US20190330353A1 (en) 2019-10-31
IL248357A0 (en) 2016-11-30
UA122390C2 (uk) 2020-11-10
AU2015250760C1 (en) 2023-11-16
IL248357B (en) 2020-05-31
RU2016145277A (ru) 2018-05-28
ES2841249T3 (es) 2021-07-07
RS61379B1 (sr) 2021-02-26
EP3783033A1 (fr) 2021-02-24
DK3134438T3 (da) 2020-12-07
BR112016024575A2 (pt) 2017-10-10
NZ725423A (en) 2023-07-28
CN112851808A (zh) 2021-05-28
JP7191134B2 (ja) 2022-12-16
CN106459204B (zh) 2021-02-02
MA39378A1 (fr) 2018-05-31

Similar Documents

Publication Publication Date Title
MA53069A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
PH12019500270A1 (en) Combination therapy for cancer
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA40913A (fr) Conjugués anticorps-médicament
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA38396A1 (fr) Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
EP4282434A3 (fr) Anticorps, leurs utilisations et leurs conjugués
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
WO2015191590A3 (fr) Polythérapies ciblant des stromas associés à une tumeur ou des cellules tumorales et des microtubules
MA37961A1 (fr) Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation
WO2015191583A3 (fr) Polythérapie ciblant des stromas ou des cellules tumorales et des topoisomérases
EA202192173A1 (ru) Анти-cd228 антитела и конъюгаты антитело-лекарственное средство
MA38502A1 (fr) Anticorps monoclonal humain isole ou son fragment de liaison a l’antigene qui se lie specifiquement a la gremlin-1 humaine utile pour le traitement des fibroses, cancers et l'inhibition de l'angiogenese